Immunogenicity Summit
2013 Archived Content

About the Summit

Get ready to join 300+ of your peers on November 11-13, 2013 in Washington, DC at the Number 1 Immunogenicity Summit in the U.S. CHI has an established reputation as a global education provider on immunogenicity. Our 2013 summit will build on last year’s successful event. With double the number of tracks this year, the Immunogenicity Summit 2013 presents technologies for safety and efficacy from bench to bedside. For early stage decision making on drug design and optimization, we examine the causes of immunogenicity together with means of mitigation, and present PK/PD and bioassay strategies. For later pre-clinical and clinical stages, we examine the complexities of immunogenicity assays, bioassays and PK/PD development, and present risk assessment strategies for smooth interaction with the regulatory authorities, and safe and efficacious products in the clinic.

SHORT COURSES - View Details 

November 10 
  • Basics of Immunogenicity Testing for Innovators and Biosimilars
  • Challenges of Immunogenicity Assessment for Innovators and Biosimilars
  • PK/PD Bioanalysis for Novel Biotherapeutics
November 12 
  • Immunogenicity Risk Assessment and Regulatory Strategy
  • Developing Potency Assays to Ensure Successful Biologics
 

Keynote Speakers

Ranjana AdvaniRanjana Advani, M.D.,
Saul A. Rosenberg Professor of Lymphoma, Professor of Medicine/Oncology,, Stanford Cancer Institute 

Kathleen ClouseKathleen Clouse, Ph.D., Director, Division of Monoclonal Antibodies, CDER/FDA 

Ira PastanIra Pastan, M.D., NIH Distinguished Investigator, Co-Chief, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health 

Max TejadaMax L. Tejada, Ph.D., Senior Scientist, Biological Technologies, Genentech, Inc. 

2013 ATTENDEE LIST - View Details 

Event Features

  • Access All 4 Conferences for One Price
  • Network with 300+ Global Attendees
  • Hear 60+ Scientific Presentations
  • Learn from FDA, Industry, and Leading Academic Research Centers
  • Dedicated Exhibit/Poster Viewing
  • Choose from 5 Short Courses
  • Interactive Roundtable, Breakout & Panel Discussions
  • Dedicated Networking Opportunities
 

What Your Peers Have
to Say About This Event:

I’m glad I attended the PK/PD meeting. Nowhere else could I find a conference entirely devoted to the in vivo activity of novel constructs. 

    - Principal Scientist, Amgen

You have succeeded in attracting the very best speaker panel I have ever seen to a meeting of this nature. 

    - Advisor, NDA Advisory Board

Congratutations on a very well put together conference. 

    - Assistant Vice President, Pfizer

Program and participants, first class. 

    - Associate Director, Novo Nordisk

Break-out interaction with FDA experts was very valuable. 

    - Associate Director, Alexion Pharmaceuticals Inc.


2013 Sponsors

Corporate Sponsors:  

antitope  


Genalyte  

 

Lonza  

 

Promega BLACK  

 

Tandem Labs  

 

Corporate Support Sponsors:  

 

BioAgilytix  

 

Precision Bioservices  

 

ProImmune  


2013 Media Partners

Lead Sponsoring Publications  

Nature_logo  

Science AAAS  

The Scientist  



Sponsoring Publications  

ADDT Logo 2  

FSG  

Insight Pharma Reports  

PharmaVoice  

Pharmaceutical Bioprocessing  

 


Web Partners  

Anitbodies  

LabRootsLogo  

Pharmaphorum  

Pharm Cast  

   
2014 Brochure Cover

Download Brochure 

Premier Sponsor : 


 Charles River(1) 



Podcast 

IMN Podcast iconReducing and Monitoring Bioassay Variability 

2013 Speaker: Janet L. Lathey, Ph.D., Director, Immunology and Assay Development, BioDefenseDivision, Emergent BioSolutions